Indo-Bangla Pharmaceuticals Limited (DSE: IBP)
Bangladesh
· Delayed Price · Currency is BDT
9.30
+0.10 (1.09%)
At close: Dec 26, 2024
DSE: IBP Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jul '22 Jul 1, 2022 | Jul '21 Jul 1, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
Revenue | 119.08 | 176.64 | 374.48 | 484.68 | 782.24 | 866.1 | Upgrade
|
Revenue Growth (YoY) | -64.80% | -52.83% | -22.74% | -38.04% | -9.68% | 16.93% | Upgrade
|
Cost of Revenue | 109.27 | 156.79 | 277.92 | 337.75 | 469.3 | 521.57 | Upgrade
|
Gross Profit | 9.81 | 19.85 | 96.56 | 146.93 | 312.94 | 344.53 | Upgrade
|
Selling, General & Admin | 38.35 | 43.61 | 67.88 | 111.13 | 139.64 | 132.71 | Upgrade
|
Operating Expenses | 38.35 | 43.61 | 67.88 | 111.13 | 139.64 | 132.71 | Upgrade
|
Operating Income | -28.54 | -23.76 | 28.68 | 35.8 | 173.3 | 211.82 | Upgrade
|
Interest Expense | -4.2 | -4.4 | -5.23 | -4.88 | -3.81 | - | Upgrade
|
Interest & Investment Income | - | - | - | - | - | 2.16 | Upgrade
|
Other Non Operating Income (Expenses) | 0.3 | 0.25 | 0.42 | 0.8 | 0.63 | 3.03 | Upgrade
|
EBT Excluding Unusual Items | -32.44 | -27.91 | 23.87 | 31.72 | 170.11 | 217.01 | Upgrade
|
Gain (Loss) on Sale of Assets | - | - | 0.7 | - | -0.77 | - | Upgrade
|
Pretax Income | -32.44 | -27.91 | 24.57 | 31.72 | 169.34 | 217.01 | Upgrade
|
Income Tax Expense | 12.54 | 13.07 | 16.17 | 6.55 | 34.62 | 60.76 | Upgrade
|
Net Income | -44.98 | -40.98 | 8.41 | 25.17 | 134.73 | 156.24 | Upgrade
|
Net Income to Common | -44.98 | -40.98 | 8.41 | 25.17 | 134.73 | 156.24 | Upgrade
|
Net Income Growth | - | - | -66.60% | -81.31% | -13.77% | 0.66% | Upgrade
|
Shares Outstanding (Basic) | 117 | 117 | 116 | 116 | 114 | 114 | Upgrade
|
Shares Outstanding (Diluted) | 117 | 117 | 116 | 116 | 114 | 114 | Upgrade
|
Shares Change (YoY) | 1.53% | 0.76% | - | 2.17% | - | 13.37% | Upgrade
|
EPS (Basic) | -0.38 | -0.35 | 0.07 | 0.22 | 1.18 | 1.37 | Upgrade
|
EPS (Diluted) | -0.38 | -0.35 | 0.07 | 0.22 | 1.18 | 1.37 | Upgrade
|
EPS Growth | - | - | -66.60% | -81.71% | -13.77% | -11.22% | Upgrade
|
Free Cash Flow | 10.68 | 23.64 | 42.92 | 47.6 | -49.39 | -133.47 | Upgrade
|
Free Cash Flow Per Share | 0.09 | 0.20 | 0.37 | 0.41 | -0.43 | -1.17 | Upgrade
|
Dividend Per Share | - | - | - | 0.100 | 0.400 | - | Upgrade
|
Dividend Growth | - | - | - | -75.00% | - | - | Upgrade
|
Gross Margin | 8.23% | 11.24% | 25.79% | 30.31% | 40.01% | 39.78% | Upgrade
|
Operating Margin | -23.97% | -13.45% | 7.66% | 7.39% | 22.15% | 24.46% | Upgrade
|
Profit Margin | -37.78% | -23.20% | 2.24% | 5.19% | 17.22% | 18.04% | Upgrade
|
Free Cash Flow Margin | 8.97% | 13.38% | 11.46% | 9.82% | -6.31% | -15.41% | Upgrade
|
EBITDA | -2.45 | 4.78 | 67.05 | 74.93 | 209.2 | 240.72 | Upgrade
|
EBITDA Margin | -2.06% | 2.71% | 17.90% | 15.46% | 26.74% | 27.79% | Upgrade
|
D&A For EBITDA | 26.09 | 28.54 | 38.36 | 39.13 | 35.9 | 28.9 | Upgrade
|
EBIT | -28.54 | -23.76 | 28.68 | 35.8 | 173.3 | 211.82 | Upgrade
|
EBIT Margin | -23.97% | -13.45% | 7.66% | 7.39% | 22.15% | 24.46% | Upgrade
|
Effective Tax Rate | - | - | 65.79% | 20.64% | 20.44% | 28.00% | Upgrade
|
Advertising Expenses | - | - | 0.77 | 4.19 | 7.02 | 7.11 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.